Skip to main content

Table 4 The associations between the COX-2 -765 G > C polymorphism and clinical characteristics of breast cancer patients

From: Functional promoter -765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women

Variables COX-2 -765 G > C genotypes P* OR (95% CI)
  GG (N, %) GC/CC (N, %)   
Tumor size     
 Less than 2 cm 116 (92.1) 10 (7.9) 0.006 1.00 (reference)
 More than 2 cm 278 (82.0) 61 (18.0)   3.01 (1.47–6.12)
LN involvement     
 Negative 206 (82.1) 45 (17.9) 0.084 1.00 (reference)
 Positive 188 (87.9) 26 (12.1)   0.63 (0.38–1.07)
ER     
 Negative 140 (86.4) 22 (13.6) 0.459 1.00 (reference)
 Positive 254 (83.8) 49 (16.2)   1.27 (0.62–2.61)
PR     
 Negative 179 (85.7) 30 (14.3) 0.620 1.00 (reference)
 Positive 215 (84.0) 41 (16.0)   0.97 (0.49–1.93)
HER-2     
 Negative 262 (84.8) 47 (15.2) 0.961 1.00 (reference)
 Positive 132 (84.6) 24 (15.4)   1.07 (0.61–1.86)
  1. ER, estrogen receptor; PR, progestin receptor; LN, lymph node; HER-2, human epidermal growth factor receptor 2; CI, confidence interval; OR, odds ratio. The frequency of the variant genotypes of COX-2 -765 G > C polymorphism was significant higher in patients with larger tumor size (>2 cm). *Two-sided χ2 test for the distributions of genotype and allele frequencies. Adjusted for tumor size, LN involvement, ER, PR and HER-2 status.